Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Short Interest Update

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) was the recipient of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 236,200 shares, a decrease of 74.3% from the January 31st total of 920,400 shares. Currently, 6.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 472,500 shares, the short-interest ratio is presently 0.5 days.

Processa Pharmaceuticals Trading Up 1.9 %

PCSA opened at $0.55 on Friday. Processa Pharmaceuticals has a 12 month low of $0.47 and a 12 month high of $3.31. The business’s 50-day moving average price is $0.73 and its 200-day moving average price is $1.06. The company has a market cap of $1.79 million, a P/E ratio of -0.16 and a beta of 0.56.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Processa Pharmaceuticals in a report on Thursday, December 5th.

Insider Transactions at Processa Pharmaceuticals

In other news, CEO George K. Ng acquired 87,200 shares of Processa Pharmaceuticals stock in a transaction dated Monday, January 27th. The shares were purchased at an average cost of $0.80 per share, for a total transaction of $69,760.00. Following the transaction, the chief executive officer now owns 87,200 shares of the company’s stock, valued at $69,760. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider David Young bought 124,500 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The stock was purchased at an average price of $0.80 per share, with a total value of $99,600.00. Following the transaction, the insider now directly owns 205,405 shares in the company, valued at $164,324. The trade was a 153.88 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 224,100 shares of company stock valued at $179,280 in the last quarter. Insiders own 13.00% of the company’s stock.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.